Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **fixed-dose combination** of two small molecule drugs: **propranolol** and **acetylsalicylic acid (ASA, also known as aspirin)**. The combination is investigated or used for its additive effects on platelet aggregation in patients with cardiovascular risk, particularly after myocardial infarction or with stable angina pectoris. Propranolol is a non-selective beta-adrenergic receptor blocker, exerting antihypertensive, antianginal, and antiarrhythmic effects by reducing heart rate, contractility, and blood pressure. Acetylsalicylic acid is a non-selective cyclooxygenase (COX) inhibitor that provides antiplatelet, anti-inflammatory, analgesic, and antipyretic actions. Together, the combination has an additive antiaggregatory effect on platelets, reducing pathological platelet aggregation more than either agent alone, which is beneficial in the secondary prevention of cardiovascular events such as myocardial infarction[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propranolol + acetylsalicylic acid.